Show simple item record

dc.contributor.authorTaylor, Justin Kyle
dc.date.accessioned2014-08-25T13:05:59Z
dc.date.available2014-08-25T13:05:59Z
dc.date.issued2014
dc.identifier.urihttp://hdl.handle.net/10713/4184
dc.descriptionUniversity of Maryland, Baltimore. Molecular Microbiology and Immunology. Ph.D. 2014en_US
dc.description.abstractSevere Acute Respiratory Syndrome (SARS) emerged in November 2002 as a case of atypical pneumonia in the Guandong Province in China. The causative agent SARS was identified as a novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV). Bone marrow stromal antigen 2 (or BST-2; also known as CD317 or tetherin) was initially identified as a pre-B-cell growth promoter but was identified as a viral antagonist. BST-2 inhibits the release of the retrovirus human immunodeficiency virus type 1 (HIV-1) virions by directly tethering budding virions from the host cell and further work has shown that BST-2 restricts the release of many other viruses, including alphaviruses, arenaviruses, herpesviruses, paramyxoviruses, and other retroviruses. BST-2 has recently been shown to restrict a human coronavirus, hCoV-229E. Many of these viruses, including hCoV-229E, are not only restricted by BST-2, but encode BST-2 antagonists to overcome BST-2 restriction. Given, the previous studies on BST-2, we aimed to determine if BST-2 has the ability to restrict SARS-CoV and if SARS-CoV encodes any BST-2 antagonists. Through an in vitro screen we identified four potential BST-2 antagonists, PL<sub>Pro</sub>, nsp1, ORF6, and ORF7a, encoded by SARS-CoV. Due to the gap in knowledge of the function of ORF7a, we focused our study on ORF7a. We found that BST-2 does restrict SARS-CoV, but the loss of ORF7a leads to a much greater restriction, which confirmed the role of ORF7a as a BST-2 antagonist. We further characterized the mechanism of BST-2 antagonism by ORF7a and found that ORF7a acts by a novel mechanism, localizes with and directly binds BST-2. ORF7a interferes with glycosylation of BST-2, although it is unclear whether ORF7a antagonizes BST-2 by blocking glycosylation or by binding to conserved patches of BST-2 and blocking glycosylation is just a side effect. We used a mouse model to evaluate the role of BST-2 in vivo and found that wild type and BST-2 -/- mice showed similar virus titer, weight loss, and lung pathology. While the BST-2 -/- mice did not show enhanced disease, there are several factors that may conceal a phenotype.en_US
dc.language.isoen_USen_US
dc.subjectBST-2en_US
dc.subjectORF7aen_US
dc.subjectSARSen_US
dc.subjecttetherinen_US
dc.subject.meshCoronavirusen_US
dc.subject.meshSevere Acute Respiratory Syndromeen_US
dc.titleBST-2 restricts SARS Coronavirus and is antagonized by SARS-CoV ORF7aen_US
dc.typedissertationen_US
dc.contributor.advisorFrieman, Matthew B.
refterms.dateFOA2019-02-19T18:05:40Z


Files in this item

Thumbnail
Name:
Taylor_umaryland_0373D_10556.pdf
Size:
45.16Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record